NCT06535854ClinicalTrials.gov
Prevail Global Study
A Randomized Controlled Study of the Prevail Drug-Coated Balloon in Subjects With In-stent Restenosis and a Single Arm Prospectively Enrolled Study of the Prevail Drug-Coated Balloon for de Novo Lesions in Small Vessel Disease (Prevail Global).
In breve
The purpose of the study is to evaluate the clinical safety and efficacy of the Prevail DCB.
Interventistico1205 partecipanti ricercati79 centri9 paesi
Categorie
Registrato in 1 registro
- ClinicalTrials.govNCT06535854Apri questa scheda su ClinicalTrials.govSincronizzato 4 settimane fa
Uno studio può essere registrato in più registri. Lo mostriamo una volta sola e colleghiamo ogni scheda in nostro possesso.
Le informazioni sulla sperimentazione sono mostrate così come pubblicate dal registro, nella lingua originale.
Ti interessa questo studio?
Accedi oppure crea un account per registrare il tuo interesse e seguire questo studio.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Present: Registered before enrolment beganFirst posted 2024-08-02; recorded start 2025-02-24
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Present: Uses blinding (masking)A masking level is recorded in the record
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 10 other studies in this databaseCounted from the lead sponsor named in the record (Medtronic Vascular)
- Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
- The record lists 1 condition.
- Lead sponsor type recorded as: industry.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A strong methodological design for a study of this type, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding7/20
Single-blind
- Control arm0/15
No comparator arm stated in the record
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre8/8
Multi-centre: 51 sites
- Data monitoring committee7/7
A data monitoring committee is in place
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A large study, international in scope: 1,205 participants (target), run at 79 sites, across 9 countries.
How this score is built
- Enrolment31/40
1,205 participants (target)
- Site count20/25
51 sites
- Country count0/15
Single country
- Planned duration10/10
Planned over about 72 months
- Sponsor scale3/10
Medtronic Vascular has led 11 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
Sintesi
The purpose of the study is to evaluate the clinical safety and efficacy of the Prevail DCB.
Patologie
- Coronary Artery Disease
Idoneità
| Sesso | Tutti |
|---|---|
| Età | 18 Years – Nessun massimo |
| Volontari sani | No |
Idoneità come riportata nel registro
Idoneità in frasi semplici
I criteri di questa scheda non sono ancora stati suddivisi in affermazioni distinte. Il testo del registro qui sopra è completo ed è la versione autorevole.
Disegno dello studio
| Tipo di studio | Interventistico |
|---|---|
| Fase | Non applicabile |
| Assegnazione | Randomizzata |
| Modello di intervento | PARALLEL |
| Finalità principale | TREATMENT |
| Mascheramento | SINGLE (1) |
| Arruolamento | 1205 partecipanti ricercati |
Sponsor e collaboratori
- Medtronic Vascular Sponsor
Bracci e interventi
- ISR Cohort Prevail DCBEXPERIMENTAL
To evaluate the clinical safety and efficacy of the Prevail DCB in the treatment of ISR with coronary lesions previously treated with drug-eluting or bare metal stents in native coronary arteries.
- DNSV Cohort (RVD 2.0 - 2.75mm)EXPERIMENTAL
To evaluate the clinical safety and efficacy of the Prevail DCB as compared to a DES historical control in subjects undergoing PCI for de novo lesions in small vessel disease.
Interventi
- Dispositivo Agent DCB
The Agent Paclitaxel-coated PTCA Balloon Catheter is intended for percutaneous transluminal coronary angioplasty (PTCA) in the coronary arteries with a vessel diameter from 2.00 mm to 4.00 mm to treat in-stent restenosis (ISR).
- Dispositivo Prevail DCB
The Prevail Paclitaxel-coated PTCA Balloon Catheter is intended for percutaneous transluminal coronary angioplasty (PTCA) in the coronary arteries with a vessel diameter from 2.00 mm to 4.00 mm to treat in-stent restenosis (ISR) and to treat de novo lesions in small vessel disease.
Esiti misurati
Esito primario
ISR Cohort Primary Analysis
The TLF rate of the Prevail DCB arm at 12 months post procedure compared to the Agent DCB arm for non-inferiority
Orizzonte temporale 1 year post-procedure
Esito primario
DNSV Cohort Primary Analysis
The TLF rate of the Prevail DCB arm at 12 months post procedure compared to a DES historical control
Orizzonte temporale 1 year post-procedure
Esito secondario
Acute success
Acute success (device, lesion, and procedure) through hospital discharge only
Orizzonte temporale hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months
Esito secondario
All deaths
Orizzonte temporale hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months
Esito secondario
Cardiac death
Orizzonte temporale hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months
Esito secondario
All myocardial infarction (MI), including target vessel myocardial infarction (TVMI)
Orizzonte temporale hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months
Esito secondario
Clinically-driven target lesion revascularization (cd-TLR) defined as repeat PCI or CABG to the target lesion
Orizzonte temporale hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months
Esito secondario
Clinically-driven target vessel revascularization (cd-TVR)
Orizzonte temporale hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months
Esito secondario
Major adverse cardiac event (MACE) defined as composite of death, MI, or repeat cd-TLR
Orizzonte temporale hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months
Esito secondario
Target lesion failure (TLF) defined as composite of cardiac death, TVMI, or cd-TLR
Orizzonte temporale hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months
Esito secondario
Target vessel failure (TVF) defined as composite of cardiac death, TVMI, or cd-TVR
Orizzonte temporale hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months
Esito secondario
Target lesion thrombosis (TLT) (definite or probable) according to Academic Research Consortium (ARC) definition
Orizzonte temporale hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months
Date
| Data di inizio | 24 febbraio 2025 (effettiva) |
|---|---|
| Conclusione primaria | 1 febbraio 2027 (stimata) |
| Conclusione | 1 febbraio 2031 (stimata) |
| Prima pubblicazione | 2 agosto 2024 (effettiva) |
| Ultimo aggiornamento | 21 ottobre 2026 |
| Risultati pubblicati | Non indicato nella scheda del registro |
| Stato verificato l'ultima volta | ottobre 2026 |
«Effettiva» significa che l'evento è avvenuto. «Stimata» significa che lo sponsor lo prevede. Le due cose non sono equivalenti.
Centri
78 centri stanno reclutando
Canada
| Struttura | Città | Stato o regione | Stato |
|---|---|---|---|
| Montreal Heart Institute | Montreal | In reclutamento | |
| Hôpital du Sacre Coeur de Montreal | Montreal | In reclutamento | |
| University of Ottawa Heart Institute | Ottawa | In reclutamento | |
| Toronto General Hospital | Toronto | In reclutamento | |
| Vancouver General Hospital | Vancouver | In reclutamento |
Germany
| Struttura | Città | Stato o regione | Stato |
|---|---|---|---|
| Herzzentrum Dresden GmbH Universitätsklinik | Dresden | In reclutamento | |
| Universitat des Saarlandes | Homburg | In reclutamento | |
| MediClin Herzzentrum Lahr / Baden | Lahr | In reclutamento |
Hong Kong
| Struttura | Città | Stato o regione | Stato |
|---|---|---|---|
| Queen Mary Hospital | Hong Kong | In reclutamento |
Ireland
| Struttura | Città | Stato o regione | Stato |
|---|---|---|---|
| Mater Private Network | Dublin | In reclutamento | |
| Galway University Hospitals - University Hospital Galway (UHG) | Galway | In reclutamento |
Japan
| Struttura | Città | Stato o regione | Stato |
|---|---|---|---|
| Teikyo University Hospital | Itabashi-ku | Tokyo | In reclutamento |
| Shonan Kamakura General Hospital | Kamakura | Kanagawa | In reclutamento |
| Kokura Memorial Hospital | Kitakyushu | Fukuoka | In reclutamento |
| Sendai Kousei Hospital | Sendai | Miyagi | In reclutamento |
| Saiseikai Yokohamashi Tobu Hospital | Yokohama | Kanagawa | In reclutamento |
Singapore
| Struttura | Città | Stato o regione | Stato |
|---|---|---|---|
| Sengkang General Hospital | Singapore | In reclutamento | |
| Tan Tock Seng Hospital | Singapore | In reclutamento |
South Korea
| Struttura | Città | Stato o regione | Stato |
|---|---|---|---|
| Keimyung University Dongsan Hospital | Daegu | In reclutamento | |
| Korea University Anam Hospital | Seoul | In reclutamento | |
| Seoul Saint Marys Hospital | Seoul | In reclutamento | |
| Seoul National University Hospital | Seoul | In reclutamento | |
| Asan Medical Center | Seoul | In reclutamento |
United Kingdom
| Struttura | Città | Stato o regione | Stato |
|---|---|---|---|
| The Newcastle upon Tyne Hospitals NHS Foundation Trust - Freeman Hospital | Newcastle upon Tyne | In reclutamento |
United States
| Struttura | Città | Stato o regione | Stato |
|---|---|---|---|
| Lehigh Valley Hospital - Cedar Crest | Allentown | Pennsylvania | In reclutamento |
| AnMed Health Medical Center | Anderson | South Carolina | In reclutamento |
| University of Michigan Health System - University Hospital | Ann Arbor | Michigan | In reclutamento |
| Emory University Hospital Midtown | Atlanta | Georgia | In reclutamento |
| Piedmont Atlanta Hospital | Atlanta | Georgia | In reclutamento |
| The University of Alabama at Birmingham | Birmingham | Alabama | In reclutamento |
| Cardiology P.C. | Birmingham | Alabama | In reclutamento |
| Kaleida Health | Buffalo | New York | In reclutamento |
| Virtua Our Lady of Lourdes Hospital | Camden | New Jersey | In reclutamento |
| Medical University of South Carolina (MUSC) | Charleston | South Carolina | In reclutamento |
| Advocate Illinois Masonic Medical Center | Chicago | Illinois | In reclutamento |
| The Lindner Research Center | Cincinnati | Ohio | In reclutamento |
| BayCare Health System | Clearwater | Florida | In reclutamento |
| University Hospitals Cleveland Medical Center | Cleveland | Ohio | In reclutamento |
| OhioHealth Riverside Methodist Hospital | Columbus | Ohio | In reclutamento |
| Baylor Heart & Vascular Hospital | Dallas | Texas | In reclutamento |
| Saint Elizabeth Healthcare | Edgewood | Kentucky | In reclutamento |
| M Health Fairview Clinic | Edina | Minnesota | Ritirato |
| Parkview Health | Fort Wayne | Indiana | In reclutamento |
| North Florida Regional Medical Center | Gainesville | Florida | In reclutamento |
| Corewell Health | Grand Rapids | Michigan | In reclutamento |
| The Moses H Cone Memorial Hospital | Greensboro | North Carolina | In reclutamento |
| UPMC Pinnacle Harrisburg Campus | Harrisburg | Pennsylvania | In reclutamento |
| HCA Houston Medical Center | Houston | Texas | In reclutamento |
| Huntsville Hospital | Huntsville | Alabama | In reclutamento |
| Saint Lukes Mid America Heart Institute | Kansas City | Missouri | In reclutamento |
Nella scheda del registro sono indicati altri 29 centri.
Documenti dello studio
In questa scheda del registro non sono collegati documenti.
Modifiche nel tempo
- 21 ottobre 2026
Centro aggiunto
28 sites added (79 total)
5179